Retrospective analysis shows TP53 mutations affect clinical outcomes in EGFR-mutant non-small cell lung cancer, suggesting implications for treatment planning.
Key Points
This research aims to investigate how different TP53 mutations affect clinical outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC).
Retrospective analysis of advanced NSCLC patients with sensitizing EGFR mutations treated with EGFR-TKIs.
Categorization of TP53 alterations into three groups based on functional domains.
Survival analyses utilizing Kaplan–Meier method and Cox proportional hazards models.
TP53 alterations observed in about half of the patients, primarily in the DNA-binding domain.
Patients receiving third-generation EGFR-TKIs had longer progression-free survival than those on earlier generations, especially with TP53 mutations.
Common EGFR mutations resulted in significantly longer progression-free survival compared to uncommon mutations, particularly with TP53 co-mutations.